Beta Lifescience articles

What is CD73?
CD73, also known as ecto-5′-nucleotidase, is a groundbreaking immunoinhibitory protein that assumes a pivotal role in tumor growth and metastasis. Its primary function revolves around converting extracellular ATP into immunosuppressive adenosine, working in tandem with CD39 within normal tissues to curtail excessive immune r

What is CD19
Understanding CD19: Definition and Role in the Immune System
CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It serves as a crucial marker for B cells, playing a pivotal role in the human immune system. While predominantly found on the surface of B cells, CD19 is rarely expressed on other immune cells. Its significance lies in its involvement in B cell development

About Tumor Suppressor Genes
A tumor suppressor gene, also known as anti-onco gene, is an essential component of the body's defense against cancer. It usually facilitates apoptosis. With its absence, the human body will be functioning without its “brake” of cell proliferation. Cells are potent to go under abnormal growth processes and finally lead to tumor/cancer.

Here are some key features and functions of tumor suppressor genes:

Low Endotoxin Cytokines Matters
Organoid culture, CAR-T cell therapy, stem cell therapy, and other topics have become broadly discussed among biomedical researchers. In fact, it is not difficult to see that these advanced technologies are all related to cell culture. In order to maintain efficient growth, proliferation, and differentiation during in vitro cell culture, many cell cultures require the addition of various cytokines.

Cytokines Backgrounds

Autoimmune disease target - IL-17 Family
IL-17 plays an important role in promoting autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis (AS). Currently, five large-molecule biopharmaceuticals targeting IL-17/IL-17R are available worldwide, including four IL-17 monoclonal antibodies and one IL-17RA monoclonal antibody, namely Secukinumab(Novartis), Ixekizumab(Eli Lilly), Netakimab(Biocad), Brodalumab(Kyowa Hakko Kirin), and Bimekizumab(U

The MMP Family
Matrix metalloproteinases (MMPs) are a family of enzymes belonging to the metzincin superfamily. There are 23 different types of secreted or membrane-anchored endopeptidases in the human body. MMPs are capable of degrading ECM proteins such as collagen, gelatin, laminin, fibronectin, fibrinogen, elastin, and proteoglycans. They were once considered regulators of the extracellular matrix. MMPs have multiple structural domains, including a signal peptide (SP

Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety for patients with high-risk or very high-risk prostate cancer. B7-H3 is expressed in limited amou

Introduction to IL-36 Family
Twenty years ago, Interleukin 36 (IL-36) was discovered as a member of the IL-1 superfamily. Its gene is located on chromosome 2 in an IL gene cluster, including IL1A - IL1B - IL37 - IL36G - IL36A - IL36B - IL36RN - IL38 - IL1RN, with IL-36 encoding genes transcribed far away from the centromere.

There are four known subtypes of IL-36, which have been renamed multiple times and were formerly known as IL-1F6, IL-1F8, IL-1F9, and IL-1F5.

Interleukin-2 (IL-2) is a 15kDa secretory protein with a 4-alpha-helical bundle structure. As a T-cell related growth factor, IL-2 can enhance the killing activity of NK cells and promote B cells to produce immunoglobulins. In addition, it aids in the development of regulatory T cells (Tregs), thereby producing peripheral T cell immune tolerance, as well as regulating the proliferation and differentiation of activated T cells. In summary, IL-2 has multiple biological functions.

IL-2 s

The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4. 

Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody-drug conjugate (ADC) that targets Nect